

Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study.

Mehmet Artac, Mahmut Emre Yildirim, Ahmet Taner Sümbül, Akin Ozturk, Nuri Karadurmus, Lokman Koral, Umut Demirci, Cagatay Arslan, Mahmut Gumus, Umut Kefeli, Ozlem Ercelep, Sinemis Celik, Oktay Bozkurt, Bala Basak Oven, Erdem Cubukcu, Mustafa Karaca, Ahmet Bilici, Deniz Tural, Hakan Harputluoglu, Faysal Dane; Necmettin Erbakan University, Meram, Turkey; Kartal Dr Lutfi kirdar Education and Research Hospital, Medical Oncology, Istanbul, Turkey; Medicalpark Adana Hospital, Adana, Turkey; Sureyyapasa Chest Disease Hospital, Istanbul, Turkey; University of Health Sciences Gülhane Education and Research Hospital, Medical Oncology, Ankara, Turkey; COM University, School of Medicine, Canakkale, Turkey; Ankara Memorial Hospital, Ankara, Turkey; Izmir Economy University Medical Point Hospital, Izmir, Turkey; Medical Oncology, Istanbul Medeniyet University Hospital, Istanbul, Turkey; Kocaeli University, School of Medicine, Izmit, Turkey; Marmara University Hospital, Istanbul, Turkey; Istanbul Oncology Hospital, Istanbul, Turkey; Erciyes University Medical Oncology, Kayseri, Turkey; Department of Medical Oncology, Yeditepe University Hospital, Istanbul, Turkey; Uludağ University Hospital, Bursa, Turkey; Health Sciences University Antalya Research and Training Hospital, Antalya, Turkey; Istanbul Medipol University, Medical Faculty, Istanbul, Turkey; University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Medical Oncology, Istanbul, Turkey; Inonu University Turgut Ozal Medical Center, Malatya, Turkey; Acibadem University, Istanbul, Turkey

Background: Evaluation of real-world data together with data in clinical studies is very important in the evaluation of treatment algorithms. In real life, treatments are applied to the elderly, patients with poor performance and unusual groups with comorbidities. Determining these treatment results is important in the creation of treatment algorithms. **Methods:** In our country, within the scope of the Registurk-Lung observational study (NCT05254119), a total of 4250 patients without driver mutation, metastatic non-small cell lung cancer were recorded between December 2021 and December 2023 in 42 centers representing the whole country. The demographic, histopathological, molecular and clinical data of the patients were recorded. The relationship between progression-free survival (PFS) time and overall survival (OS) time with these characteristics was investigated. **Results:** 4250 patients were evaluated. The median age was 64 (26–90) years and 15.1% of the patients were female. The proportion of patients who never smoked was 10.4 %. Histopathologically, 36.4% of the patients were diagnosed with squamous cell carcinoma. PDL-1 level was higher than 50% in 24.0% of patients and < 1 in 40.4% of patients. Only 11.8 percent of patients received single agent immunotherapy or chemoimmunotherapy. Other patients had received only a combination of doublet chemotherapy. The PFS was 6.9 months (95% CI: 6.4–7.3) and OS 14.6 (95% CI: 12.3–16.8) months in the whole patient group. Compared to the group that received chemotherapy alone, PFS and overall survival were longer in the group that received chemoimmunotherapy. This difference between the two groups was found to be statistically significant (p:0,001 and 0,031 respectively). **Conclusions:** As shown in clinical studies, immunotherapy alone or chemoimmunotherapy according to PDL-1 expression status provides a significant survival contribution compared to chemotherapy alone. Research Sponsor: None.